Suppr超能文献

临床医生开具伏立康唑治疗药物监测医嘱的实践:一家转诊实验室的经验。

Clinician ordering practices for voriconazole therapeutic drug monitoring: experiences of a referral laboratory.

机构信息

Department of Microbiology and Infectious Diseases, St. Vincent's Hospital, Sydney, New South Wales, Australia.

出版信息

Ther Drug Monit. 2010 Oct;32(5):661-4. doi: 10.1097/FTD.0b013e3181ea3de6.

Abstract

Monitoring of serum voriconazole concentrations has been proposed to optimize therapeutic effect and minimize toxicity. However, little is known about the clinical use of voriconazole therapeutic drug monitoring (TDM) by treating physicians. Four hundred seventy-eight episodes corresponding with 161 adult patients (mean three TDM episodes per patient; range 1-31, at a mean interval 43.6 days [range 1-266] between repetitions) performed at a state reference laboratory in Australia during a 30-month period were reviewed. Information about voriconazole dose was provided on only nine (1.9%) request forms. Timing of voriconazole TDM in relation to the previous dose was stated in 189 (39%) episodes and corresponded with peak measurements in 16; interval measurements (taken on average 3.3 [range 3-10.5] hours from the preceding dose) in 15; and trough measurements in 158 episodes. Of the 158 trough concentration measurements, only 66 (42%) were between 1 and 5.5 mg/L, the suggested therapeutic range. Similarly, only 33% (98 of 298) of all the random TDM episodes achieved voriconazole concentrations greater than 2.05 mg/L, previously associated with favorable outcomes. Compared with trough TDM, random episodes were significantly more likely to result in undetectable (less than 0.1 mg/L) concentrations (45 of 298 [15.1%] versus 12 of 158 [7.6%]; P = 0.021, odds ratio 2.16, 95% confidence interval: 1.11-4.22). Among patients with multiple TDM episodes, there was no correlation between the initial and final trough or between the initial and final random concentrations. Only 44% (eight of 18) of patients with multiple trough TDM had final concentration within 1 to 5.5 mg/L; and only 26% (15 of 58) of patients with multiple random TDM had final concentration greater than 2.05 mg/L. Adoption of consistent and clear guidelines on voriconazole TDM use and education of physicians ordering the test is required because the majority of testing performed was inappropriate and prone to suboptimal interpretation.

摘要

监测伏立康唑的血清浓度已被提议用于优化治疗效果并最小化毒性。然而,治疗医师对伏立康唑治疗药物监测(TDM)的临床应用知之甚少。在澳大利亚的一个州参考实验室进行的 30 个月期间,回顾了 161 例成年患者的 478 例(平均每个患者 3 次 TDM 检测;范围为 1-31 次,两次重复之间的平均间隔为 43.6 天[范围为 1-266 天])。只有 9 份(1.9%)申请表提供了伏立康唑剂量的信息。189 次(39%)TDM 检测与上次剂量有关,其中 16 次检测到峰值,15 次检测到间隔测量(平均在之前剂量后 3.3 小时[范围 3-10.5 小时]),158 次检测到谷值。在 158 次谷浓度测量中,只有 66 次(42%)在 1 至 5.5mg/L 之间,这是建议的治疗范围。同样,只有 33%(298 次中 98 次)所有随机 TDM 检测的伏立康唑浓度均大于 2.05mg/L,之前与良好的结果相关。与谷值 TDM 相比,随机检测更有可能导致无法检测到(小于 0.1mg/L)的浓度(298 次中有 45 次[15.1%],而 158 次中有 12 次[7.6%];P=0.021,优势比 2.16,95%置信区间:1.11-4.22)。在有多次 TDM 检测的患者中,初始和最终谷值或初始和最终随机浓度之间没有相关性。只有 44%(18 次中有 8 次)有多次谷值 TDM 的患者最终浓度在 1 至 5.5mg/L 之间;只有 26%(58 次中有 15 次)有多次随机 TDM 的患者最终浓度大于 2.05mg/L。需要采用关于伏立康唑 TDM 使用的一致和明确的指南并对开具检测的医生进行教育,因为大多数检测都不适当且容易导致解释不佳。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验